Introduction
Correction of metabolic acidosis, a cardinal manifestation of late stage CKD, is one of the goals of effective dialysis. In patients with CKD, uncorrected metabolic acidosis leads to clinically significant consequences like protein energy wasting and bone disease, and in hemodialysis (HD) patients, it is associated with higher death risk (1) (2) (3) (4) (5) (6) (7) . Clinical trials have shown that correction of metabolic acidosis results in improvements in protein energy wasting and reduction of hospitalizations of peritoneal dialysis (PD) patients (8, 9) . Furthermore, high-normal arterial pH is associated with more positive nitrogen balances than low-normal pH in PD patients (10) . Animal studies have also indicated that metabolic acidosis is associated with development or worsening of proteinuria and exacerbation of tubulointerstitial injury, and in humans with CKD in a randomized controlled clinical trial, correction of metabolic acidosis was shown to attenuate the rate of decline in renal function (11) (12) (13) . These data may be applicable to ESRD, because residual renal function is an important predictor of survival of HD and PD patients (14, 15) .
Despite the risks associated with uncorrected metabolic acidosis and the demonstrable benefits with its treatment, almost one-half of HD patients evaluated in a large study had suboptimal correction of metabolic acidosis (7) . To our knowledge, there are no data comparing the effectiveness of PD with HD in the correction of metabolic acidosis. Furthermore, there is no consensus whether the therapeutic targets for serum bicarbonate should differ by dialysis modality (16) (17) (18) (19) (20) . We undertook this study to test the hypothesis that PD provides a more complete correction of metabolic acidosis and that the serum bicarbonate level below which the death risk is increased in patients does not vary by dialysis modality.
Materials and Methods

Data Source
This observational cohort study uses data from maintenance dialysis patients treated in DaVita facilities between July 1, 2001 and June 30, 2006 who were followed through June of 2007, and it is linked to the data from the US Renal Data System (USRDS). Data from DaVita were used to determine subjects' age, sex, diabetes status, body weight, height, and dialysis modality. The USRDS data were used to determine the day of first dialysis, race/ethnicity, marital status, primary insurance, eight comorbid conditions at start of dialysis therapy, and date and cause of death.
The initial study cohort consisted of 164,801 patients. Patients were assigned to the dialysis modality used at the time of entry into the cohort. The following patients were excluded: patients with unknown or missing data on dialysis modality and patients who died, underwent renal transplantation, were lost to follow-up by day 90 from the first dialysis treatment (n=13,711), and were at extremes of age (#16 or $99 years; n=7588). Furthermore, data for baseline serum bicarbonate were missing for 22,151 patients (PD: 1,658, 14%; HD: 20,493, 16%). Hence, the final cohort consisted of 121,351 subjects (PD=10,400; HD=110,951). Supplemental Table 1 
Statistical Methods
Complete data were available for age, sex, race, and diabetes. Data for comorbidities were missing for 5%. Insurance status was missing for 9%, marital status was missing for 21%, body mass index was missing for 7%, parathyroid hormone was missing for 12%, serum total iron binding capacity, ferritin, and creatinine, and lymphocyte percentage were missing for 1%-2%, and serum albumin, calcium, phosphorus, and alkaline phosphatase, and white blood cell count and hemoglobin were missing for ,1%. The frequency of missing data was similar for both dialysis modalities, except for body mass index (missing: PD=41%; HD=3%). Missing data were imputed for the continuous variables using median, comorbid conditions using mean, and other categorical data using prevalence among individuals with complete data. a Age, sex, diabetes, race/ethnicity, primary insurance, marital status, vintage category (,6 months, 6 months to 2 years, 2-5 years, and .5 years), atherosclerotic heart disease, congestive heart failure, other cardiac diseases, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, cancer, and tobacco smoking. b Case mix variables plus body mass index, serum albumin, creatinine, ferritin, total iron binding capacity, calcium, phosphorus, parathyroid hormone, alkaline phosphatase, hemoglobin, white blood cell count, and percent lymphocyte.
Logistic regression analysis was used to compare the odds of having serum bicarbonate below three different thresholds (,20, ,22, and ,24 mEq/L) for PD patients using HD as reference. Survival analyses using Cox proportional hazard regression were performed to determine the relationship between time-averaged serum bicarbonate with all-cause, cardiovascular, and infection-related mortality in (1) PD patients and (2) the combined PD-HD cohort. The outcomes were assigned to the dialysis modality at time of entry into the study cohort. For each regression analysis, three levels of adjustment were examined: (1) unadjusted; (2) case mix-adjusted, including age, sex, race/ ethnicity, presence of diabetes, eight comorbid conditions, four categories of dialysis vintage, primary insurance status, and marital status as additional covariates; and (3) case mix and laboratory data-adjusted with body mass index, serum total iron binding capacity, ferritin, creatinine, calcium, phosphorus, alkaline phosphatase, parathyroid hormone, albumin, white blood cell count, lymphocyte percentage, and hemoglobin as additional covariates. The population-attributable risk of death caused by timeaveraged serum bicarbonate,22 mEq/L in PD and HD patients was calculated as P e 3 (RR 2 1)/RR, where P e is the prevalence of low serum bicarbonate among all who died and RR is the relative risk of death (21) .
All analyses were carried out using STATA, version 10.1 (StataCorp LP, College Station, TX; www.stata.com).
Results
Patient Characteristics
Baseline characteristics of the cohort stratified by dialysis modality are listed in Table 1 . PD patients were younger, were more likely to be white, were less likely to have diabetes and other comorbid conditions, had higher serum creatinine, total iron binding capacity, and parathyroid hormone levels, and had lower serum ferritin level. (Table 2 ). Serum potassium level was progressively higher with lower serum bicarbonate levels (serum potassium with bicarbonate,19 mEq/L: PD=5.060.6, HD=4.960.5; serum potassium with serum bicarbonate$27 mEq/L: PD=4.060.5, HD=4.460.6). Thus, there was a progressive increase in proportion of patients with timeaveraged serum potassium.5.5 mEq/L with declining serum bicarbonate levels (for serum bicarbonate,19 mEq/L, PD=10% and HD=15%; for serum bicarbonate$27 mEq/L, PD=0.5% and HD=3%).
Completeness of correction of metabolic acidosis in HD patients was associated with the dialysate bicarbonate levels (Supplemental Table 2 ). Although 53% of patients dialyzed against a time-averaged bath bicarbonate concentration of 30 to ,33 mEq/L had serum bicarbonate,22 mEq/L, 36% of patients dialyzed against a bath concentration of 39 to #40 mEq/L had that level (Figure 2 ). For each strata of serum and dialysate bicarbonate, the mean single-pool Kt/V urea was significantly higher than the minimum value considered an adequate dialysis dose (Supplemental Table 3 ).
Serum Bicarbonate and Death Risk in PD Patients
With increasing time-averaged serum bicarbonate, PD patients were older, were more likely to be diabetic and have cardiovascular comorbidities, had shorter dialysis vintage, and had lower serum creatinine, ferritin, phosphorus, and parathyroid hormone levels (Table 3) .
On follow-up of the 10,400 PD patients, 2912 (28%) patients received a kidney transplant, and 4710 (45%) patients died S e x( %f e m a l e ) (Figure 3 and Table 4 ). However, there was no association between serum bicarbonate levels and infection-related mortality. Inclusion of serum potassium as a covariate attenuated the hazards ratio for all-cause and cardiovascular mortality in PD patients with time-averaged serum bicarbonate levels,19 mEq/L, but it had no meaningful effect in other subgroups.
Comparison of Association of Serum Bicarbonate with Death Risk in PD and HD Patients
On follow-up of the 110,951 HD patients, 13,540 (12%) patients received a kidney transplant, and 60,087 (54%) patients died (cardiovascular=24,695; infectionrelated=10,628). For this analysis, HD patients with timeaveraged pre-HD serum bicarbonate of 24 to ,25 mEq/L were used as the reference group. The adjusted risk for allcause mortality was higher in most subgroups with serum bicarbonate,22 mEq/L, irrespective of the dialysis modality ( Figure 4 and Table 5 ). Although there was no graded relationship between serum bicarbonate and cardiovascular or infection-related mortality in PD patients, a higher risk was seen in HD patients with serum bicarbonate of ,24 and ,22 mEq/L, respectively ( Figure 4 and Table 5 ). Inclusion of serum potassium as a covariate had no meaningful effect on hazards ratio for any of the outcomes in any of the subgroups examined. The population-attributable risks for all-cause mortality with time-averaged serum bicarbonate,22 mEq/L in PD and HD patients were 2.3% (0.07, 4.6) and 5.6% (4.6, 6.7), respectively.
Sensitivity Analyses
Three sets of sensitivity analyses were performed. In the first analysis, only individuals with complete data for all variables were included (PD=3050; HD=60,589). The same qualitative trends were observed with a few exceptionsunlike the primary analysis, infection-related mortality was higher in PD patients with time-average serum bicarbonate$27 mEq/L (Supplemental Table 4 ). Furthermore, in the analysis using the combined PD and HD cohort, cardiovascular mortality was also higher with time-averaged serum bicarbonate,19 mEq/L in PD patients (Supplemental Table 4 ). In the second sensitivity analysis, models were built after excluding marital status and body mass index-covariates with the highest proportion of missing data. All-cause and cardiovascular mortality was higher in both PD patients and the entire PD-HD cohort with time-averaged serum bicarbonate,20 and ,22 mEq/L, respectively (Supplemental Tables 5 and 6 ). In the third sensitivity analysis, 3 mEq/L was added to the measured predialysis serum bicarbonate of HD patients to yield an adjusted bicarbonate value to account for the interdialytic variation in the control of metabolic acidosis. Survival analyses were repeated in the PD-HD cohort, with HD patients with adjusted serum bicarbonate=26 to ,27 as reference. The general trend of higher all-cause and cardiovascular mortality with higher death risk was Data adjusted for age, sex, race and/or ethnicity, diabetes, dialysis vintage (,6 months, 6 months to 2 years, 2-5 years, and .5 years), primary insurance, marital status, atherosclerotic heart disease, congestive heart failure, cerebrovascular disease, other cardiac diseases, peripheral vascular disease, chronic obstructive pulmonary disease, cancer, current smoking, body mass index, serum albumin, total iron binding capacity, ferritin, creatinine, calcium, phosphorus, parathyroid hormone, alkaline phosphatase, hemoglobin, white blood cell count, and percentage lymphocyte count. Data adjusted for age, sex, race and/or ethnicity, diabetes, dialysis vintage (,6 months, 6 months to 2 years, 2-5 years, and .5 years), primary insurance, marital status, atherosclerotic heart disease, congestive heart failure, cerebrovascular disease, other cardiac diseases, peripheral vascular disease, chronic obstructive pulmonary disease, cancer, current smoking, body mass index, serum albumin, total iron binding capacity, ferritin, creatinine, calcium, phosphorus, parathyroid hormone, alkaline phosphatase, hemoglobin, white blood cell count, and percentage lymphocyte count. HD, hemodialysis; PD, peritoneal dialysis.
observed, albeit with different thresholds for each dialysis modality (Supplemental Table 7 ).
Discussion
Our study allows us to make a few key observations. First, between 2001 and 2006, a substantial proportion of maintenance dialysis patients in the United States had an inadequate correction of uremic metabolic acidosis; complete correction was more likely with PD (PD=75%; HD=60%). Second, this study is the first to report an association between serum bicarbonate and death risk in PD patients and shows that the threshold below which death risk is higher is the same irrespective of dialysis modality (,22 mEq/L).
The present study is the largest evaluation of the adequacy of correction of metabolic acidosis, and to our knowledge, it is the first comprehensive comparison of PD and HD patients. There was a large difference in the proportion of PD and HD patients with time-averaged serum bicarbonate,22 mEq/L-25% and 40%, respectively. The previous studies that had evaluated the distribution of serum bicarbonate levels in PD patients were limited, because they were derived from a single center and/or had small sample sizes. In two single-center studies, serum bicarbonate was ,22 mEq/L in 21% and 16% of patients, respectively (n=43 and n=79, respectively) (22, 23) . In contrast, a larger study reported a lower prevalence of uncorrected metabolic acidosis in PD patients (n=252; serum bicarbonate,22 mEq/L=10%-12%) (24) . The significantly higher prevalence of serum bicarbonate levels,22 mEq/L in HD patients is similar to earlier reports. Thus, a previous analysis reported that 49% of the HD patients had serum bicarbonate,22 mEq/L at an earlier time period (7). Similarly, two other studies have shown that one-third to onehalf of HD patients have inadequate correction of metabolic acidosis (n=7123 and 1000, respectively) (25, 26) .
One of the reasons for the higher prevalence of low serum bicarbonate levels in our study may be that the measurements were made in samples shipped overnight to a central laboratory; this practice has been shown to result in lower serum bicarbonate levels (27) . Nevertheless, almost 80% of dialysis patients in the United States are treated in facilities owned by large dialysis organizations (28) ; all laboratory specimens in these facilities are shipped overnight to a central laboratory. Hence, our findings have substantial external validity in the United States. Moreover, the effect is unlikely to vary by dialysis modality, and thus, our finding of differential correction of metabolic acidosis by modality remains robust.
Several explanations for the large differences observed by dialysis modality can be considered. First, the measured serum bicarbonate in PD patients is an equilibrated value. In contrast, HD is an intermittent therapy, with a saw-tooth pattern of metabolic control, and the pre-HD serum bicarbonate is the lowest value for the patient. Second, notwithstanding the timing of measurement, it is conceivable that PD may be more effective in correcting metabolic acidosis because of the continuous nature of the therapy. Third, differences may, in part, be caused by differences in concentrations of the buffer in the dialysate. Although the peritoneal dialysate contains 40 mEq/L lactate, most HD patients are dialyzed against bath bicarbonate with #35 mEq/L.
To our knowledge, this study is the first to show an increased death risk with low serum bicarbonate in PD patients. The results of at least three previous studies that have examined this question in HD patients have been inconsistent; our study builds on these previous findings. In a landmark study of prognostic predictors for HD patients, the work by Lowrie and Lew (5) reported an increased death risk with serum bicarbonate,17.5 or .25 mEq/L. However, the study reported only univariate associations (5) . Analysis of data from the Dialysis Outcomes and Practice Patterns also showed a higher adjusted death risk for HD patients with predialysis bicarbonate,17 or .27 mEq/L, with the lowest mortality in patients with serum bicarbonate of 20.1-21.0 mEq/L (6). In the largest study to have examined this issue before our current analysis, a reverse J-shaped pattern between serum bicarbonate and mortality was noted, with lower death risk with serum bicarbonate.22 mEq/L (7). These findings are consistent with our observation of a higher death risk with time-averaged bicarbonate levels,22 mEq/L. The use of time-averaged values in this study provides a more robust association with death risk than has been reported thus far.
The mechanisms whereby uncorrected metabolic acidosis may increase the death risk of dialysis patients are unclear. Low arterial pH is associated with hyperkalemia from a transcellular shift of potassium, a significant predictor of death risk (29, 30) . In our cohort, the likelihood of significant hyperkalemia increased with decrease in serum bicarbonate. Acidosis also induces protein energy wasting through increased protein catabolism, decreased protein synthesis, and increased insulin resistance (1) (2) (3) (4) . Other potential mechanisms include systemic inflammation and a more rapid loss of residual renal function (11) (12) (13) (31) (32) (33) (34) (35) . Furthermore, metabolic acidosis leads to a net calcium efflux from the bone, which in turn, can lead to fragility fractures and is associated with a higher death risk in HD patients (36, 37) .
Although there are no clinical trials that show that correction of metabolic acidosis tangibly improves any hard outcomes in dialysis patients, our study lends support to the argument for a more aggressive approach to the problem. Correction of metabolic acidosis has been associated with improvements in important intermediate measures in PD patients or patients at earlier stages of CKD. Thus, in a clinical trial using peritoneal dialysate with 35 versus 40 mEq/L lactate, at the end of 12 months, patients treated with the latter had higher increase in body weight, greater midarm circumference, and fewer hospitalizations (9) . In another clinical trial, PD patients treated with oral sodium bicarbonate to achieve a serum bicarbonate level of 26-28 mEq/L had better subjective global assessment scores, higher normalized protein catabolic rates, and fewer hospitalizations (8) . Consistent with these findings, an arterial pH of 7.45 was associated with more positive nitrogen balances in seven of eight PD patients compared with a pH of 7.37 (10) . Finally, correction of metabolic acidosis has been shown to slow the rate of decline of renal function (11) (12) (13) .
To date, there has been no consensus among expert groups whether the target serum bicarbonate levels should vary by dialysis modality. Clinical practice guidelines from the National Kidney Foundation Disease Outcomes Quality Initiative recommend serum bicarbonate levels$22 mEq/L, irrespective of dialysis modality (16, 17) . In contrast, the United Kingdom Renal Association recommends serum bicarbonate to be within the normal range for PD patients but provides greater latitude for HD patients (target predialysis values=18-24 mEq/L) (18, 19) . Similarly, the European Best Practice Guidelines recommend achieving bicarbonate levels$25 mEq/L for PD patients but 20-22 mEq/L for HD patients (20) . To our knowledge, this study provides the first comparison of the level of serum bicarbonate below which death risk goes up in HD and PD patients using values as they are measured in clinical practice. Given that death risk increased with serum bicarbonate levels,22 mEq/L in both HD and PD patients, our study suggests that the targets should not vary by dialysis modality.
Our study is not without limitations. First, there were some variables for which information was not available for all patients. We undertook several sensitivity analyses to determine the impact of this limitation, each of which produced similar findings. Second, information on some potential confounders, like serum C-reactive protein or residual renal function, was missing. We attempted to overcome this limitation by adjusting for surrogates for inflammation and dialysis vintage, respectively. Third, data on adherence to dialysis regimen and information about PD prescription modality (continuous ambulatory or automated PD), solute clearances, or peritoneal transport rate were unavailable. Fourth, although information on small solute clearances was available for HD patients, it was not available for PD patients. The overwhelming majority of dialysis patients in the United States achieves the recommended targets for dialysis adequacy. Indeed, in 2005, 93% each of PD and HD patients had a weekly Kt/V urea $1.7 or per-session single-pool Kt/V urea $1.2 (38) . Fifth, this study reports data from 2001 to 2006, and practices may have changed since that time. Finally, data on comorbidity were obtained from the time of start of dialysis, and the use of Medical Evidence Form 2728 may have led us to underestimate the prevalence of different comorbid conditions (39) .
In conclusion, our study shows that uncorrected metabolic acidosis is more likely to be present in HD than PD patients. Given the consistent association of low bicarbonate levels with higher death risk and the absence of an adequately powered clinical trial, all attempts should be made to correct uremic metabolic acidosis.
